Klaria Pharma Holding AB

As of June 30, 2026, Klaria Pharma Holding AB carries a market capitalization of 194.08M, placing it among publicly traded companies globally. Its enterprise value stands at 185.61M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Klaria Pharma Holding AB's next confirmed earnings release is scheduled for November 26, 2026.

As of June 30, 2026, Klaria Pharma Holding AB has 245.98M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 1,235.12, and the price-to-book ratio stands at -5.77.

These figures are as of June 30, 2026. The EV/Sales ratio of 1,213.13 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 185.61M versus a market cap of 194.08M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Klaria Pharma Holding AB maintains a current ratio of 0.20, meaning it holds 0.2x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026. Return on assets (ROA) is negative at -88.24, reflecting losses generated across the asset base. The company generates approximately 38,250.00 in revenue per employee across its workforce of 4.00, a quick read on workforce productivity versus industry peers.

As of the close on October 22, 2026, Klaria Pharma Holding AB's stock has gained approximately 16.28% over the past 52 weeks. The 50-day moving average sits at 0.68, while the 200-day moving average is 0.82.

Over the twelve months ended June 30, 2026, Klaria Pharma Holding AB generated 153,000.00 in revenue and converted that into -38.72M in net income, yielding earnings per share of -0.16. EBITDA reached -23.18M, while operating income came in at -31.61M.

These figures are as of June 30, 2026. Total book value stands at -33.61M, with working capital of -48.82M providing operational flexibility.

Klaria Pharma Holding AB produced -48.51M in operating cash flow over the twelve months ended June 30, 2026. After subtracting - - in capital expenditures, free cash flow totaled -48.51M - equivalent to -0.20 per share.

These figures cover the twelve months ended June 30, 2026. The operating margin of -20,660.13 and net profit margin of -25,306.54 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -25.59: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -28.35, meaning Klaria Pharma Holding AB raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Klaria Pharma Holding AB's most recent stock split took place on June 19, 2025 with a 116:119 split ratio.

As of June 30, 2026, Klaria Pharma Holding AB has an Altman Z-Score of -13.54, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.